Progression Risk in Barrett Esophagus That Is “Indefinite for Dysplasia”

Active inflammation and abnormal DNA flow cytometry results were risk factors for neoplastic progression.

Guideline recommendations are well established for management of low-grade dysplasia (LGD) or high-grade dysplasia (HGD) in patients with Barrett esophagus (BE) but not for pathology findings of “indefinite for dysplasia (IND).” To determine the incidence and predictors of subsequent neoplastic progression in patients with IND findings, expert gastrointestinal pathologists from a well-known center of excellence for BE assessed histologic findings and DNA flow cytometry data from follow-up of 96 patients with IND.

At 1, 2, and 3 years of follow-up, rates of progression to LGD, HGD, or esophageal adenocarcinoma (EAC) were 25%, 37%, and 47%, respectively, and rates of progression to HGD or EAC were 10%, 13%, and 20%, respectively. Significant r…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors